FDA "Critical Path" Faces Roadblock
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency plans to release its list of top priorities several months behind schedule while it focuses on drug safety issues, Acting Deputy Commissioner Woodcock says. Limited FDA resources may jeopardize the project as well.
You may also be interested in...
"Critical Path" Priorities List Likely To Include Clinical Trial Design, FDAer Says
FDA expects to release its Critical Path opportunities list by the end of the summer. Issues concerning clinical trial design and biomarkers appeared "orders of magnitude" more often than other topics in stakeholder comments, FDA Regulatory Counsel Rovin says at BIO annual meeting.
"Critical Path" Priorities List Likely To Include Clinical Trial Design, FDAer Says
FDA expects to release its Critical Path opportunities list by the end of the summer. Issues concerning clinical trial design and biomarkers appeared "orders of magnitude" more often than other topics in stakeholder comments, FDA Regulatory Counsel Rovin says at BIO annual meeting.
Senate Drug Safety Hearings Will Take Broad View Of FDA Process
The Senate Health Committee is planning a series of hearings on drug safety issues in March on topics including FDA’s drug approval process and the delayed “Critical Path” drug development initiative. It is premature to predict how drug safety controversies will impact FDA post-marketing authority, House and Senate staffers say.